Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.
CONCLUSION: The PASCO I study contributes significantly to current knowledge about the frequency of adverse events associated with the use of epoetin-ζ for the treatment of renal anemia and demonstrates a pattern of adverse events comparable with data for other existing epoetin products in Europe.
PMID: 26396097 [PubMed - as supplied by publisher]
Source: Clinical Nephrology - Category: Urology & Nephrology Authors: Dellanna F, Fluck RJ, Lonnemann G, Wild CA, Iwanowitsch A, Meissner R, Audhya P Tags: Clin Nephrol Source Type: research
More News: Accidents | Anemia | European Medicines Agency (EMA) | Heart Attack | Kidney Transplant | Pulmonary Thromboembolism | Sports Medicine | Study | Thrombosis | Urology & Nephrology